NCT07117058 Validation of a Rapid Screening Tool for Anxiety-depressive Disorders in Children, Adolescents and Young Adults Treated in Oncology. Multicenter Study.
| NCT ID | NCT07117058 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Generalized Anxiety |
| Study Type | OBSERVATIONAL |
| Enrollment | 545 participants |
| Start Date | 2025-03-18 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 545 participants in total. It began in 2025-03-18 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In France today, it is estimated that one in every 850 people aged between 20 and 45 is a childhood cancer survivor (CCS), equivalent to around 40,000 to 50,000 people. Some descriptive studies have established that the diagnosis and treatment of cancer can affect psychological health. A French study published by our team in 2015 and 2020 showed that in adulthood, 40% of CCS had anxiety symptoms, a rate significantly higher than that of the general French population (25%). However, although there are validated scales for screening children for psychological disorders (anxiety, depression, etc.), there is no rapid screening tool that can be used routinely by an oncologist during consultations. So, the study aims to develop and validate a short test, which could easily be carried out systematically during follow-up consultations after childhood cancer. It would make it possible to identify people with no psychological complications and, conversely, those in whom further investigation, based on the classic reference scales for assessing psychological disorders, would be relevant.
Eligibility Criteria
Inclusion Criteria * Patients diagnosed with pediatric cancer before the age of 18, * Patient whose intensive treatment had ended at least 3 months prior to inclusion, * Patients considered to be in complete remission by the doctor responsible for their treatment, * Patient affiliated to or entitled under a social security scheme, * Patient having received informed information about the study OR the holder(s) of parental authority having received informed information about the study in the case of minors. Exclusion Criteria * Refusal to participate expressed by the patient or minor, * Patients whose cancer has relapsed or progressed, * Pregnant women, women in labor, breast-feeding mothers, * Persons deprived of their liberty, hospitalized without consent, hospitalized for purposes other than those of the research, * Adults under legal protection (guardianship) or unable to express their consent.
Contact & Investigator
CLAIRE BERGER, MD
PRINCIPAL INVESTIGATOR
Centre Hospitalier Universitaire de Saint Etienne
Frequently Asked Questions
Who can join the NCT07117058 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 25 Years, studying Generalized Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07117058 currently recruiting?
Yes, NCT07117058 is actively recruiting participants. Contact the research team at claire.berger@chu-st-etienne.fr for enrollment information.
Where is the NCT07117058 trial being conducted?
This trial is being conducted at Caen, France, Grenoble, France, Lyon, France, Nice, France and 3 additional locations.
Who is sponsoring the NCT07117058 clinical trial?
NCT07117058 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is CLAIRE BERGER, MD at Centre Hospitalier Universitaire de Saint Etienne. The trial plans to enroll 545 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.